Expedited regulatory pathways offer a powerful advantage for sponsors developing therapies that address serious or unmet medical needs. But navigating Fast Track, Breakthrough Therapy, Priority Review, Accelerated Approval, PRIME, and other accelerated options requires strategic planning, cross-functional alignment, and evidence packages that withstand rigorous scrutiny.

This eBook distills the evolving FDA and EMA expedited landscape including insights from PDUFA VII into a practical, easy-to-follow guide designed for clinical, regulatory, and development teams. Whether you are evaluating your first expedited designation or refining established processes, the guidance in this resource will help your teams move with speed and confidence.

Drawing from MMS’s extensive experience supporting accelerated submissions across therapeutic areas, this guide highlights best practices for early regulatory engagement, statistical planning, global alignment, and managing the operational demands of compressed timelines. It provides the clarity needed to reduce uncertainty and advance innovative therapies efficiently.

A Practical Guide to Expedited Regulatory Pathways

Download your eBook today ↓

Key Benefits:

• Identify the most appropriate expedited pathways for your program and data maturity.
• Engage FDA and EMA stakeholders early to shape trial design, endpoints, and evidence expectations.
• Integrate statistical, clinical, and CMC strategy to support accelerated timelines.
• Navigate global programs such as PRIME, Conditional Marketing Authorization, Project Orbis, and RTOR.
• Strengthen operational readiness for rolling reviews, interim analyses, and confirmatory studies.

This guide is completely free and built for teams navigating today’s rapidly evolving regulatory environment. Download now to stay ahead of requirements and accelerate your path to approval with confidence.